- Companies
- Pelago
Pelago Funding, Investors & Competitors
Pelago has raised $153M across 6 funding rounds, most recently a $58M Series C in March 2024.
Last Pelago funding round
$58M
Series C · Mar 2024
Cumulative funding Pelago raised
$153M
across 6 funding rounds
Key investors in Pelago
Y Combinator
Octopus Ventures
Atomico
Kinnevik
StartUp Health
Triple Point Venture VCT
Burda Principal Investments
Eight Roads Ventures
About Pelago
Pelago, formerly known as Quit Genius, is a virtual clinic that provides digital, evidence-based treatment for substance use disorders including tobacco, alcohol, opioid, and cannabis addiction. Using cognitive behavioral therapy, medication-assisted treatment, and live clinical support, the company partners with employers and health plans across all 50 US states to deliver telehealth care for adults and teenagers. Pelago serves clients such as MetLife, Philips, and GE Appliances, covering more than 3.4 million eligible lives, and operates on an at-risk payment model tied to clinical outcomes.
Founded
2017
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Services
Pelago Funding History
Pelago has raised a total of $153M across 6 funding rounds.
Pelago's first fundraising round was a $3M seed round in May 2018. The most recent completed round was a $58M Series C in March 2024.
Pelago funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Mar 2024 | Series C | Atomico (lead); Octopus Ventures; Y Combinator; Kinnevik; Eight Roads Ventures; GreyMatter | $58M | Pelago, a digital clinic providing substance use management solutions to U.S. businesses and health plans, raised $58 million in a Series C funding round on March 28, 2024, led by existing investor Atomico, with participation from Kinnevik AB, Octopus Ventures, Y Combinator, and new investors Eight Roads and GreyMatter Capital. This brought total funding to $151 million since its founding in 2017 as Quit Genius. The capital will accelerate product roadmap development, extend the continuum of care including adolescent services, and advance clinical research efforts. The round follows strong demand for substance use disorder (SUD) management as an essential employee benefit, with Pelago reporting 287% revenue growth in 2023, 100% client retention, an 11x revenue surge since its 2021 Series B, and a 500% increase in SUD-specific RFPs from employers and payers over the past year. The platform covers more than 3.4 million eligible lives, with clients including MetLife, Phillips, and GE Appliances. Pelago operates at-risk with performance guarantees, getting paid only upon successful population-level clinical outcomes. Pelago differentiates by offering specialized virtual treatments for tobacco, alcohol, and opioid use disorders across all acuity levels and co-occurring mental health conditions, available in 50 states for adults and teens aged 15-17. It has introduced innovations like the AI-powered Pelago Chart for clinical note-taking and expanded services amid rising SUD needs not fully addressed by general mental health or EAP solutions. Headcount tripled from 50 in 2021 to 150, reflecting rapid scaling. Atomico Partner Laura Connell joined the board, highlighting investor confidence in Pelago's leadership in the SUD space. |
| Jul 2022 | Series B | - | $15M | Pelago raised $15 million in a Series B funding round in July 2022 to further develop its platform and expand market reach. This followed a $64 million Series B in July 2021 led by Atomico and Kinnevik. The company, founded in 2017 as Quit Genius, provides virtual care for substance use disorders including alcohol, tobacco, and opioids, operating as a digital clinical partner to U.S. businesses and health plans. |
| Jul 2021 | Series B | Atomico (lead); Kinnevik (lead); Octopus Ventures; StartUp Health; Product Co-op; Triple Point Venture VCT | $64M | Pelago (formerly Quit Genius) is a Y Combinator-backed virtual clinic providing digital-first, evidence-based support for substance use disorders including tobacco, alcohol, opioids, and cannabis, using cognitive behavioral therapy, medication-assisted treatment, and live clinical support available across 50 US states for adults and teens. The company partners with employers and health plans to offer stigma-free telehealth care, aiming to reduce healthcare costs. In July 2021, Pelago raised $64 million in a Series B round led by Atomico and Kinnevik, with participation from Octopus Ventures and others, to expand services amid rising telehealth demand during the COVID pandemic. Valuation was not publicly disclosed. Total funding reached $151 million by March 2024 Series C. Post-Series B, Pelago tripled headcount from 50 to 150, introduced AI tools like Pelago Chart, and expanded to adolescent services. By 2023, it achieved 287% revenue growth and 100% client retention, with an 11x revenue surge since Series B reported in 2024, though baseline revenue undisclosed. Kinnevik holds a 14% stake as of 2025 reports. Pelago competes in the growing digital mental health and addiction treatment market, backed by 30 investors including Y Combinator, Eight Roads, and GreyMatter Capital. |
| Oct 2020 | Undisclosed stage | Burda Principal Investments (lead) | $2M | Quit Genius, the digital addiction-treatment provider that now trades as Pelago, raised a further USD 1.5 million from Burda Principal Investments in the second half of 2020. The financing followed the company's USD 11 million Series A led by Octopus Ventures in March 2020. Quit Genius provides app-based treatment programmes for tobacco, alcohol and opioid addiction, sold through employers and health plans. |
| Mar 2020 | Series A | Octopus Ventures (lead); Y Combinator; StartUp Health; Burda Principal Investments; Venus Williams; Serena Ventures; Cur8 Capital; Triple Point Venture VCT | $12M | Pelago, formerly Quit Genius, is a virtual clinic providing personalized, digital-first support for managing substance use disorders including tobacco, alcohol, opioid, and cannabis, using evidence-based tools and live clinical support to reduce healthcare costs and offer stigma-free care. The company raised $12 million in its Series A round in March 2020, led by Octopus Ventures, to expand into opioid and alcohol addiction treatment. Investors included Burda Principal Investments, Cur8 Capital, Serena Ventures, StartUp Health, Triple Point Ventures, Venus Williams, and Y Combinator. Pelago has raised a total of $151.6 million across seven rounds, with subsequent funding including a $64 million Series B in July 2021 led by Atomico and Kinnevik, and a $58 million Series C in March 2024 led by Atomico. |
| May 2018 | Seed | Max Mullen; M Ventures; Junaid Bajwa; Y Combinator; Force Over Mass Capital; Eric Ries; Lionheart Ventures; David Langer; Telefónica; EQT Ventures; AAF Management Ltd.; Juha Paananen | $3M | Pelago raised $2.6 million in a seed round in May 2018 to expand the team and enhance the platform's capabilities. Investors included AAF Management Ltd., David Langer, EQT Ventures, Eric Ries, Force Over Mass Capital, Juha Paananen, Junaid Bajwa, Lionheart Ventures, Max Mullen, Merck, Telefonica, and Y Combinator. Valuation at the round was not publicly disclosed. Pelago, formerly Quit Genius, provides virtual substance use management, offering personalized care for alcohol, tobacco, opioid, and cannabis use through physician-led teams, cognitive behavioral therapy, medication-assisted treatment, and remote monitoring tools. The company partners with health plans, employers, and individuals, serving adults and adolescents across all 50 states. The company has since raised additional rounds, including a $12 million Series A in March 2020 led by Octopus Ventures to expand into opioid and alcohol addiction treatment, a Series B of $64 million, and a $58 million Series C in March 2024 led by Atomico, bringing total funding to $151 million. Recent growth includes 287% revenue growth in 2023 and coverage of over 3.4 million eligible lives. |
Who has invested in Pelago?
24 investors have backed Pelago across its funding rounds, including Y Combinator, Octopus Ventures, Atomico, Kinnevik, StartUp Health and Triple Point Venture VCT.
Lead investors include Atomico, Kinnevik, Burda Principal Investments and Octopus Ventures.
Pelago Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | Mar 2020 | ||
| 3 | Participant | May 2018 | ||
| 2 | Participant | Mar 2020 | ||
| 2 | Lead | Mar 2020 | ||
| 2 | Lead | Jul 2021 | ||
| 2 | Participant | Mar 2020 | ||
| 2 | Lead | Jul 2021 | ||
| 1 | Participant | May 2018 | ||
| 1 | Participant | May 2018 | ||
| 1 | Participant | May 2018 | ||
| 1 | Participant | May 2018 | ||
| 1 | Participant | May 2018 | ||
| 1 | Participant | May 2018 | ||
This data is available for Pro users. Sign up to see all 24 Pelago investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialPelago Competitors
Pelago competitors include listed companies like Hims and Compass Pathways, and private ones like Workit Health, Ro, Cerebral and Sword Health.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | - | - | $500M | - | ||
| Private | $598M | - | $7B | 11.7x | ||
| Publicly listed | $2.3B | $178M | $6.5B | 2.4x | ||
| Private | - | - | $4.8B | - | ||
| Private | $240M | - | $4B | 16.7x | ||
| Publicly listed | - | ($293M) | $2.1B | - |
Pelago Public Comps
Pelago is still privately-owned, but its public comps include Humana Inc., Max Healthcare Institute, Oscar Health, Hims, Doximity, ACADIA Pharmaceuticals, Compass Pathways, Alignment Healthcare, Ping An Healthcare and JMDC.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $130B | $3B | 0.4x | 0.3x | 17.8x | 16.6x | |||
| $858M | $232M | 12.6x | 10.2x | 46.5x | 36.8x | |||
| $12B | ($391M) | 0.5x | 0.4x | (15.9x) | 12.8x | |||
| $2.3B | $178M | 3.1x | 2.4x | 40.4x | 23.9x | |||
| $645M | $229M | 6.3x | 6.2x | 17.7x | 11.9x | |||
| $1.1B | $119M | 3.6x | 3.2x | 32.3x | 33.6x | |||
| - | ($293M) | - | - | (5.8x) | (8.4x) | |||
| $3.9B | $45M | 0.4x | 0.3x | 31.6x | 10.0x | |||
This data is available for Pro users. Sign up to see all Pelago competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Pelago
| When was Pelago founded? | Pelago was founded in 2017. |
| Where is Pelago headquartered? | Pelago is headquartered in New York City, NY, United States. |
| Is Pelago publicly listed? | No, Pelago is a private, VC-backed company. |
| How much funding has Pelago raised? | Pelago has raised $153M across 6 funding rounds. |
| What was Pelago's last funding round? | Pelago's last funding round was a $58M Series C in March 2024, led by Atomico. |
| Who are Pelago's investors? | Pelago's investors include Octopus Ventures, Y Combinator, StartUp Health, Burda Principal Investments, Kinnevik, Triple Point Venture VCT, Atomico, Max Mullen, M Ventures, Junaid Bajwa and 14 others. |
| Which companies are comparable to Pelago? | Companies comparable to Pelago include Workit Health, Ro, Hims, Cerebral, Sword Health and Compass Pathways. |
See companies similar to Pelago
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




